ABPI 1, NICE 0: industry shifts pricing influence away from UK HTA body
This article was originally published in Scrip
Executive Summary
The UK pharma industry association, the ABPI, has won a victory over NICE, the health technology appraisal institute for England and Wales, in the ongoing negotiations over value-based pricing. Currently, NICE sets the cost-effectiveness thresholds that influence UK drug pricing and the role of NICE itself was outside the ABPI’s sphere of influence. But the ABPI's chief executive Stephen Whitehead told Scrip that those thresholds are now part of the negotiations rather than being outside them.